West Pharmaceutical Services IncWST
Price$370.76Intrinsic value$309.5717% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $309.57median of 6 methods · middle span $297-$358based on filings through 30 Jun 2026
Market Price $370.76Price as of 30 Sep 2026
Margin of Safety -16.5%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 14.5% (near-term consensus, capped) · years 2–5: 16.3%/yr (balance of the path).15.9% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 615.7%Yr 715.1%Yr 814.5%Yr 913.9%Yr 1013.3%
16.3% → 13.3%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1112.3%Yr 1211.2%Yr 1310.2%Yr 149.2%Yr 158.2%Yr 167.1%Yr 176.1%Yr 185.1%Yr 194.0%Yr 203.0%
13.3% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)13.3%
Discount rate (cost of equity) 9.8%
Volatility vs market (adjusted beta)1.09

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetWest Pharmaceutical Services IncWSTHealth Care
Valuation
P/E47.5×
P/S7.8×
P/B8.8×
EV / Revenue7.7×
EV / EBITDA29.3×
Profitability
Gross margin35.9%
Operating margin19.0%
Net margin17.0%
FCF margin13.1%
Returns
ROE18.9%
ROA13.9%
ROIC20.5%
Growth
Revenue growth (YoY)15.0%
5-yr fwd EPS growth15.9%
Financial strength
Debt / Equity0.07×
Current ratio2.82×
Altman Z-Score17.7
Interest coverage—
Dividend yield0.3%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.